PDCD1 and neoplasm: PD-1/PD-L1 monoclonal antibody disrupts tumor immune tolerance by specifically blocking PD-1/PD-L1 interaction, restoring the killing function of tumor-specific T cells and achieving tumor clearance (Figure 1F) (13).